Does lowering cholesterol have an impact on the progression of aortic stenosis?

Therapeutic Advances in Cardiovascular Disease

Volumn 2, Issue 4, 2008, Pages 277-286

  Greve, Anders M ^a   Wachtell, Kristian ^a  

^a International Center for Research and Research Training in Endocrine Disruption of Male Reproduction and Child Health   (Denmark)

Author keywords

And Hyperlipidemia; Aortic Stenosis; Calcification; Cholesterol; Pathogenesis; Statin

Indexed keywords

ATORVASTATIN; BIOLOGICAL MARKER; CHOLESTEROL; EZETIMIBE; FLUINDOSTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PLACEBO; ROSUVASTATIN; SIMVASTATIN;

ANTIINFLAMMATORY ACTIVITY; AORTA STENOSIS; ARTERY CALCIFICATION; CHOLESTEROL BLOOD LEVEL; CLINICAL FEATURE; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; DRUG MECHANISM; ECHOCARDIOGRAPHY; ENDOTHELIAL DYSFUNCTION; HEART LEFT VENTRICLE EJECTION FRACTION; HISTOPATHOLOGY; HUMAN; HYPERCHOLESTEROLEMIA; INFLAMMATION; NONHUMAN; OUTCOME ASSESSMENT; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW; RISK FACTOR;

AORTIC VALVE; AORTIC VALVE STENOSIS; CALCINOSIS; CLINICAL TRIALS AS TOPIC; ENDOTHELIUM, VASCULAR; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERLIPIDEMIAS; RISK FACTORS;

EID: 68649086160     PISSN: 17539447     EISSN: None     Source Type: Journal    
DOI: 10.1177/1753944708093935     Document Type: Review

References (58)

1. Antonini-Canterin, F., Popescu, B.A., Huang, G., Korcova-Miertusova, R., Rivaben, D., Faggiano, P. et al. (2005) Progression of aortic valve sclerosis and aortic valve stenosis: what is the role of statin treatment? Ital Heart J 6: 119-124.
2. Blankenberg, S., Barbaux, S. and Tiret, L. (2003) Adhesion molecules and atherosclerosis. Atherosclerosis 170: 191-203.
3. Bonow, R.O., Carabello, B.A., Kanu, C., de Jr, L.A., Faxon, D.P., Freed, M.D. et al. (2006) ACC / AHA 2006 guidelines for the management of patients with valvular heart disease: a report of the American College of Cardiology / American Heart Association Task Force on Practice Guidelines (writing committee to revise the 1998 Guidelines for the Management of Patients With Valvular Heart Disease): developed in collaboration with the Society of Cardiovascular Anesthesiologists: endorsed by the Society for Cardiovascular Angiography and Interventions and the Society of Thoracic Surgeons. Circulation 114: e84-231.
4. Chan, K.L. (2003) Is aortic stenosis a preventable disease? J Am Coll Cardiol 42: 593-599.
5. Chan, K.L. and Teo, K. (2005) Lipid-lowering therapy in calcific aortic stenosis. N Engl J Med 353: 1066-1067.
6. Chan, K.L., Teo, K., Tam, J. and Dumesnil, J.G. (2007) Rationale, design, and baseline characteristics of a randomized trial to assess the effect of cholesterol lowering on the progression of aortic stenosis: the Aortic Stenosis Progression Observation: Measuring Effects of Rosuvastatin (ASTRONOMER) trial. Am Heart J 153: 925-931.
7. Cote, C., Pibarot, P., Despres, J.P., Mohty, D., Cartier, A., Arsenault, B. et al. (2007) Association between circulating oxidized low-density lipoprotein and fibro-calcific remodeling of the aortic valve in aortic stenosis. Heart published online doi:10.1136/hrt.2007.125740.
8. Cowell, S.J., Newby, D.E., Prescott, R.J., Bloomfield, P., Reid, J., Northridge, D.B. et al. (2005) A randomized trial of intensive lipid-lowering therapy in calcific aortic stenosis. N Engl J Med 352: 2389-2397.
9. Dawkins, S., Hobson, A.R., Kalra, P.R., Tang, A.T., Monro, J.L. and Dawkins, K.D. (2008) Permanent pacemaker implantation after isolated aortic valve replacement: incidence, indications, and predictors. Ann Thorac Surg 85: 108-112.
10. de Boer, O.J., van der Wal, A.C., Teeling, P. and Becker, A.E. (1999) Leucocyte recruitment in rupture prone regions of lipid-rich plaques: a prominent role for neovascularization? Cardiovasc Res 41: 443-449.
11. Eckel, R.H., Grundy, S.M. and Zimmet, P.Z. (2005) The metabolic syndrome. Lancet 365: 1415-1428.
12. Freeman, R.V., Crittenden, G. and Otto, C. (2004) Acquired aortic stenosis. Expert Rev Cardiovasc Ther 2: 107-116.
13. Freeman, R.V. and Otto, C.M. (2005) Spectrum of calcific aortic valve disease: pathogenesis, disease progression, and treatment strategies. Circulation 111: 3316-3326.
14. Garg, V. ( 2006) Molecular genetics of aortic valve disease. Curr Opin Cardiol. 21: 180-184.
15. Griffin, B.P. (2007) The effect of lipitor in aortic stenosis. http://clinicaltrials.gov/ct2/show/NCT00590135ID:NCT00590135.
16. Iivanainen, A.M., Lindroos, M., Tilvis, R., Heikkila, J. and Kupari, M. (1996) Natural history of aortic valve stenosis of varying severity in the elderly. Am J Cardiol 78: 97-101.
17. Katz, R., Wong, N.D., Kronmal, R., Takasu, J., Shavelle, D.M., Probstfield, J.L. et al. (2006) Features of the metabolic syndrome and diabetes mellitus as predictors of aortic valve calcification in the Multi-Ethnic Study of Atherosclerosis. Circulation 113: 2113-2119.
18. Kizu, A., Shioi, A., Jono, S., Koyama, H., Okuno, Y. and Nishizawa, Y. (2004) Statins inhibit in vitro calcification of human vascular smooth muscle cells induced by inflammatory mediators. J Cell Biochem 93: 1011-1019.
19. Kuiper, J., van Puijvelde, G.H., van Wanrooij, E.J., van Es, T., Habets, K., Hauer, A.D. et al. (2007) Immunomodulation of the inflammatory response in atherosclerosis. Curr Opin Lipidol 18: 521-526.
20. Laissy, J.P., Messika-Zeitoun, D., Serfaty, J.M., Sebban, V., Schouman-Claeys, E., Iung, B. et al. (2007) Comprehensive evaluation of preoperative patients with aortic valve stenosis: usefulness of cardiac multidetector computed tomography. Heart 93: 1121-1125.
21. Lester, S.J., Heilbron, B., Gin, K., Dodek, A. and Jue, J. (1998) The natural history and rate of progression of aortic stenosis. Chest 113: 1109-1114.
22. Lindroos, M., Kupari, M., Heikkila, J. and Tilvis, R. (1993) Prevalence of aortic valve abnormalities in the elderly: an echocardiographic study of a random population sample. J Am Coll Cardiol 21: 1220-1225.
23. Martinez, M.W. and Nishimura, R.A. (2006) Approach to the patient with aortic stenosis and low ejection fraction. Curr Cardiol Rep 8: 90-95.
24. Mays, M.E. and Dujovne, C.A. (2008) Pleiotropic effects: should statins be considered an essential component in the treatment of dyslipidemia? Curr Atheroscler Rep 10: 45-52.
25. Mazzone, A., Epistolato, M.C., Gianetti, J., Castagnini, M., Sassi, C., Ceravolo, R. et al. (2006) Biological features (inflammation and neoangiogenesis) and atherosclerotic risk factors in carotid plaques and calcified aortic valve stenosis: two different sites of the same disease? Am J Clin Pathol 126: 494-502.
26. Messika-Zeitoun, D., Aubry, M.C., Detaint, D., Bielak, L.F., Peyser, P.A., Sheedy, P.F. et al. (2004) Evaluation and clinical implications of aortic valve calcification measured by electron-beam computed tomography. Circulation 110: 356-362.
27. Mohler, E.R., III. (2004) Mechanisms of aortic valve calcification. Am J Cardiol 94: 1396-1402, A6.
28. Mohler, E.R.I., III, Medenilla, E., Wang, H. and Scott, C. (2006) Aortic valve calcium content does not predict aortic valve area. J Heart Valve Dis 15: 322-328.
29. Mohler, E.R., III, Wang, H., Medenilla, E. and Scott, C. (2007) Effect of statin treatment on aortic valve and coronary artery calcification. J Heart Valve Dis 16: 378-386.
30. Mohty, D., Pibarot, P., Despres, J.P., Cote, C., Arsenault, B., Cartier, A. et al. (2008) Association between plasma LDL particle size, valvular accumulation of oxidized LDL, and inflammation in patients with aortic stenosis. Arterioscler Thromb Vasc Biol 28: 187-193.
31. Moura, L.M., Ramos, S.F., Zamorano, J.L., Barros, I.M., Azevedo, L.F., Rocha-Goncalves, F. et al. (2007) Rosuvastatin affecting aortic valve endothelium to slow the progression of aortic stenosis. J Am Coll Cardiol 49: 554-561.
32. Nordestgaard, B.G. and Nielsen, L.B. (1994) Atherosclerosis and arterial influx of lipoproteins. Curr Opin Lipidol 5: 252-257.
33. Novaro, G.M., Katz, R., Aviles, R.J., Gottdiener, J.S., Cushman, M., Psaty, B.M. et al. (2007) Clinical factors, but not C-reactive protein, predict progression of calcific aortic-valve disease: the Cardiovascular Health Study. J Am Coll Cardiol 50: 1992-1998.
34. O'Brien, K.D. (2006) Pathogenesis of calcific aortic valve disease: a disease process comes of age (and a good deal more). Arterioscler Thromb Vasc Biol 26: 1721-1728.
35. O'Brien, K.D., Reichenbach, D.D., Marcovina, S.M., Kuusisto, J., Alpers, C.E. and Otto, C.M. (1996) Apolipoproteins B, (a), and E accumulate in the morphologically early lesion of ‘degenerative’ valvular aortic stenosis. Arterioscler Thromb Vasc Biol 16: 523-532.
36. O'Regan, C., Wu, P., Arora, P., Perri, D. and Mills, E.J. (2008) Statin therapy in stroke prevention: a meta-analysis involving 121,000 patients. Am J Med 121: 24-33.
37. Otto, C.M., Burwash, I.G., Legget, M.E., Munt, B.I., Fujioka, M., Healy, N.L. et al. (1997) Prospective study of asymptomatic valvular aortic stenosis. Clinical, echocardiographic, and exercise predictors of outcome. Circulation 95: 2262-2270.
38. Otto, C.M., Kuusisto, J., Reichenbach, D.D., Gown, A.M. and O'Brien, K.D. (1994) Characterization of the early lesion of ‘degenerative’ valvular aortic stenosis. Histological and immunohistochemical studies. Circulation 90: 844-853.
39. Pellikka, P.A., Sarano, M.E., Nishimura, R.A., Malouf, J.F., Bailey, K.R., Scott, C.G. et al. (2005) Outcome of 622 adults with asymptomatic, hemodynamically significant aortic stenosis during prolonged follow-up. Circulation 111: 3290-3295.
40. Rajamannan, N.M., Bonow, R.O. and Rahimtoola, S.H. (2007) Calcific aortic stenosis: an update. Nat Clin Pract Cardiovasc Med 4: 254-262.
41. Rajamannan, N.M., Subramaniam, M., Caira, F., Stock, S.R. and Spelsberg, T.C. (2005) Atorvastatin inhibits hypercholesterolemia-induced calcification in the aortic valves via the Lrp 5 receptor pathway. Circulation 112: 1229-1234.
42. Rizzo, M. and Berneis, K. (2006) The clinical relevance of low-density-lipoproteins size modulation by statins. Cardiovasc Drugs Ther 20: 205-217.
43. Rosenhek, R., Binder, T., Porenta, G., Lang, I., Christ, G., Schemper, M. et al. (2000) Predictors of outcome in severe, asymptomatic aortic stenosis. N Engl J Med 343: 611-617.
44. Ross Jr, J. and Braunwald, E. (1968) Aortic stenosis. Circulation 38: 61-67.
45. Rossebo, A.B., Pedersen, T.R., Allen, C., Boman, K., Chambers, J., Egstrup, K. et al. (2007) Design and baseline characteristics of the simvastatin and ezetimibe in aortic stenosis (SEAS) study. Am J Cardiol 99: 970-973.
46. Sanchez, P.L. (2006) Randomized study to evaluate the efficacy of fluvastatin on inflammatory markers in patients with aortic stenosis. http://clinicaltrials.gov/ct2/show/NCT00590135ID:NCT00590135.
47. Sanchez, P.L., Santos, J.L., Kaski, J.C., Cruz, I., Arribas, A., Villacorta, E. et al. (2006) Relation of circulating C-reactive protein to progression of aortic valve stenosis. Am J Cardiol 97: 90-93.
48. Schuler, G. (2005) Statin therapy in asymptomatic aortic stenosis. http://clinicaltrials.gov/ct2/show/NCT00176410ID:NCT00176410.
49. Selwyn, A.P. (2007) Antiatherosclerotic effects of statins: LDL versus non-LDL effects. Curr Atheroscler Rep 9: 281-285.
50. Shively, B.K., Charlton, G.A., Crawford, M.H., Chaney, R.K. (1998) Flow dependence of valve area in aortic stenosis: relation to valve morphology. J Am Coll Cardiol 31: 654-660.
51. St Pierre, A.C., Cantin, B., Dagenais, G.R., Mauriege, P., Bernard, P.M., Despres, J.P. et al. (2005) Low-density lipoprotein subfractions and the long-term risk of ischemic heart disease in men: 13-year follow-up data from the Quebec Cardiovascular Study. Arterioscler Thromb Vasc Biol 25: 553-559.
52. Stewart, B.F., Siscovick, D., Lind, B.K., Gardin, J.M., Gottdiener, J.S., Smith, V.E. et al. (1997) Clinical factors associated with calcific aortic valve disease. Cardiovascular Health Study. J AmColl Cardiol 29: 630-634.
53. Tabas, I., Williams, K.J. and Boren, J. (2007) Subendothelial lipoprotein retention as the initiating process in atherosclerosis: update and therapeutic implications. Circulation 116: 1832-1844.
54. Ward, S., Lloyd, J.M., Pandor, A., Holmes, M., Ara, R., Ryan, A. et al. (2007) A systematic review and economic evaluation of statins for the prevention of coronary events. Health Technol Assess 11: 1-iv.
55. Warren, B.A. and Yong, J.L. (1997) Calcification of the aortic valve: its progression and grading. Pathology 29: 360-368.
56. Weber, M., Hausen, M., Arnold, R., Nef, H., Moellman, H. and Berkowitsch, A. et al. (2006) Prognostic value of N-terminal pro-B-type natriuretic peptide for conservatively and surgically treated patients with aortic valve stenosis. Heart 92: 1639-1644.
57. Wen, Y. and Leake, D.S. (2007) Low density lipoprotein undergoes oxidation within lysosomes in cells. Circ Res 100: 1337-1343.
58. Williams, K.J. and Tabas, I. (1995) The response-to-retention hypothesis of early atherogenesis. Arterioscler Thromb Vasc Biol 15: 551-561.